Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy
Abstract
:1. Introduction
2. Muscle Protein Synthesis and IGF-1 Signaling
3. Muscle Protein Synthesis: Myostatin
4. Muscle Protein Degradation: UPS
5. Muscle Protein Degradation: Autophagy
6. Muscle Energy Homeostasis: AMPK and IGF-1
7. Alternative Splicing of IGF-1 mRNA to Produce a Local Form
8. IGF-1 Binding Proteins in Skeletal Muscle
9. Skeletal Muscle-Specific IGF-1/IGF-1R Gene Deletion Studies
10. IGF-1, Satellite Cells and Skeletal Muscle Regeneration
11. Atrophy-Related miRs and Their Potential Regulation of IGF-1 Signaling
12. IGF-1 Changes in Chronic Conditions and Aging-Associated Sarcopenia
13. Conclusions
Funding
Conflicts of Interest
References
- Stein, A.M.; Silva, T.M.V.; Coelho, F.G.M.; Arantes, F.J.; Costa, J.L.R.; Teodoro, E.; Santos-Galduroz, R.F. Physical exercise, IGF-1 and cognition A systematic review of experimental studies in the elderly. Dement. Neuropsychol. 2018, 12, 114–122. [Google Scholar] [CrossRef]
- Majorczyk, M.; Smolag, D. Effect of physical activity on IGF-1 and IGFBP levels in the context of civilization diseases prevention. Rocz. Panstw. Zakl. Hig. 2016, 67, 105–111. [Google Scholar]
- Nindl, B.C.; Santtila, M.; Vaara, J.; Hakkinen, K.; Kyrolainen, H. Circulating IGF-I is associated with fitness and health outcomes in a population of 846 young healthy men. Growth Horm. IGF Res. 2011, 21, 124–128. [Google Scholar] [CrossRef]
- Maggio, M.; De Vita, F.; Lauretani, F.; Butto, V.; Bondi, G.; Cattabiani, C.; Nouvenne, A.; Meschi, T.; Dall’Aglio, E.; Ceda, G.P. IGF-1, the cross road of the nutritional, inflammatory and hormonal pathways to frailty. Nutrients 2013, 5, 4184–4205. [Google Scholar] [CrossRef] [Green Version]
- Puche, J.E.; Castilla-Cortazar, I. Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J. Transl. Med. 2012, 10, 224. [Google Scholar] [CrossRef] [Green Version]
- Rommel, C.; Bodine, S.C.; Clarke, B.A.; Rossman, R.; Nunez, L.; Stitt, T.N.; Yancopoulos, G.D.; Glass, D.J. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3, 1009–1013. [Google Scholar] [CrossRef]
- Peng, X.D.; Xu, P.Z.; Chen, M.L.; Hahn-Windgassen, A.; Skeen, J.; Jacobs, J.; Sundararajan, D.; Chen, W.S.; Crawford, S.E.; Coleman, K.G.; et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003, 17, 1352–1365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bodine, S.C.; Latres, E.; Baumhueter, S.; Lai, V.K.; Nunez, L.; Clarke, B.A.; Poueymirou, W.T.; Panaro, F.J.; Na, E.; Dharmarajan, K.; et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294, 1704–1708. [Google Scholar] [CrossRef]
- Pallafacchina, G.; Calabria, E.; Serrano, A.L.; Kalhovde, J.M.; Schiaffino, S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. USA 2002, 99, 9213–9218. [Google Scholar] [CrossRef] [Green Version]
- Glass, D.J. Molecular mechanisms modulating muscle mass. Trends Mol. Med. 2003, 9, 344–350. [Google Scholar] [CrossRef]
- Gruner, S.; Peter, D.; Weber, R.; Wohlbold, L.; Chung, M.Y.; Weichenrieder, O.; Valkov, E.; Igreja, C.; Izaurralde, E. The structures of eIF4E-eIF4G complexes reveal an extended interface to regulate translation initiation. Mol. Cell 2016, 64, 467–479. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bodine, S.C.; Stitt, T.N.; Gonzalez, M.; Kline, W.O.; Stover, G.L.; Bauerlein, R.; Zlotchenko, E.; Scrimgeour, A.; Lawrence, J.C.; Glass, D.J.; et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001, 3, 1014–1019. [Google Scholar] [CrossRef]
- Desbois-Mouthon, C.; Cadoret, A.; Blivet-Van Eggelpoel, M.J.; Bertrand, F.; Cherqui, G.; Perret, C.; Capeau, J. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001, 20, 252–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Armstrong, D.D.; Esser, K.A. Wnt/beta-catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy. Am. J. Physiol. Cell Physiol. 2005, 289, C853–C859. [Google Scholar] [CrossRef]
- Schakman, O.; Kalista, S.; Bertrand, L.; Lause, P.; Verniers, J.; Ketelslegers, J.M.; Thissen, J.P. Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology 2008, 149, 3900–3908. [Google Scholar] [CrossRef] [PubMed]
- Yoon, M.S. MTOR as a key regulator in maintaining skeletal muscle mass. Front. Physiol. 2017, 8, 788. [Google Scholar] [CrossRef] [Green Version]
- Verhees, K.J.; Schols, A.M.; Kelders, M.C.; Op den Kamp, C.M.; van der Velden, J.L.; Langen, R.C. Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 2011, 301, C995–C1007. [Google Scholar] [CrossRef]
- Pansters, N.A.; Schols, A.M.; Verhees, K.J.; de Theije, C.C.; Snepvangers, F.J.; Kelders, M.C.; Ubags, N.D.; Haegens, A.; Langen, R.C. Muscle-specific GSK-3beta ablation accelerates regeneration of disuse-atrophied skeletal muscle. Biochim. Biophys. Acta 2015, 1852, 490–506. [Google Scholar] [CrossRef] [Green Version]
- Verhees, K.J.; Pansters, N.A.; Baarsma, H.A.; Remels, A.H.; Haegens, A.; de Theije, C.C.; Schols, A.M.; Gosens, R.; Langen, R.C. Pharmacological inhibition of GSK-3 in a guinea pig model of LPS-induced pulmonary inflammation: II. Effects on skeletal muscle atrophy. Respir. Res. 2013, 14, 117. [Google Scholar] [CrossRef] [Green Version]
- McPherron, A.C.; Lawler, A.M.; Lee, S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387, 83–90. [Google Scholar] [CrossRef]
- Morissette, M.R.; Cook, S.A.; Buranasombati, C.; Rosenberg, M.A.; Rosenzweig, A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am. J. Physiol. Cell Physiol. 2009, 297, C1124–C1132. [Google Scholar] [CrossRef] [Green Version]
- Taylor, W.E.; Bhasin, S.; Artaza, J.; Byhower, F.; Azam, M.; Willard, D.H., Jr.; Kull, F.C., Jr.; Gonzalez-Cadavid, N. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E221–E228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trendelenburg, A.U.; Meyer, A.; Rohner, D.; Boyle, J.; Hatakeyama, S.; Glass, D.J. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 2009, 296, C1258–C1270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lipina, C.; Kendall, H.; McPherron, A.C.; Taylor, P.M.; Hundal, H.S. Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice. FEBS Lett. 2010, 584, 2403–2408. [Google Scholar] [CrossRef] [Green Version]
- Hennebry, A.; Oldham, J.; Shavlakadze, T.; Grounds, M.D.; Sheard, P.; Fiorotto, M.L.; Falconer, S.; Smith, H.K.; Berry, C.; Jeanplong, F.; et al. IGF1 stimulates greater muscle hypertrophy in the absence of myostatin in male mice. J. Endocrinol. 2017, 234, 187–200. [Google Scholar] [CrossRef] [Green Version]
- Sartori, R.; Schirwis, E.; Blaauw, B.; Bortolanza, S.; Zhao, J.; Enzo, E.; Stantzou, A.; Mouisel, E.; Toniolo, L.; Ferry, A.; et al. BMP signaling controls muscle mass. Nat. Genet. 2013, 45, 1309–1318. [Google Scholar] [CrossRef] [PubMed]
- Sartori, R.; Milan, G.; Patron, M.; Mammucari, C.; Blaauw, B.; Abraham, R.; Sandri, M. Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol. 2009, 296, C1248–C1257. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Zhou, F.; Ten Dijke, P. Signaling interplay between transforming growth factor-beta receptor and PI3K/AKT pathways in cancer. Trends Biochem. Sci. 2013, 38, 612–620. [Google Scholar] [CrossRef]
- Bilodeau, P.A.; Coyne, E.S.; Wing, S.S. The ubiquitin proteasome system in atrophying skeletal muscle: Roles and regulation. Am. J. Physiol. Cell Physiol. 2016, 311, C392–C403. [Google Scholar] [CrossRef] [Green Version]
- Attaix, D.; Ventadour, S.; Codran, A.; Bechet, D.; Taillandier, D.; Combaret, L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem. 2005, 41, 173–186. [Google Scholar] [CrossRef]
- Bodine, S.C.; Baehr, L.M. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am. J. Physiol. Endocrinol. Metab. 2014, 307, E469–E484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoshida, T.; Delafontaine, P. Mechanisms of cachexia in chronic disease states. Am. J. Med. Sci. 2015, 350, 250–256. [Google Scholar] [CrossRef] [Green Version]
- McLoughlin, T.J.; Smith, S.M.; DeLong, A.D.; Wang, H.; Unterman, T.G.; Esser, K.A. FoxO1 induces apoptosis in skeletal myotubes in a DNA-binding-dependent manner. Am. J. Physiol. Cell Physiol. 2009, 297, C548–C555. [Google Scholar] [CrossRef] [PubMed]
- Senf, S.M.; Dodd, S.L.; Judge, A.R. FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am. J. Physiol. Cell Physiol. 2010, 298, C38–C45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cai, D.; Frantz, J.D.; Tawa, N.E., Jr.; Melendez, P.A.; Oh, B.C.; Lidov, H.G.; Hasselgren, P.O.; Frontera, W.R.; Lee, J.; Glass, D.J.; et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119, 285–298. [Google Scholar] [CrossRef] [Green Version]
- Wu, C.L.; Cornwell, E.W.; Jackman, R.W.; Kandarian, S.C. NF-kappaB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy. Am. J. Physiol. Cell Physiol. 2014, 306, C762–C767. [Google Scholar] [CrossRef]
- Tilstra, J.S.; Clauson, C.L.; Niedernhofer, L.J.; Robbins, P.D. NF-kappaB in aging and disease. Aging Dis. 2011, 2, 449–465. [Google Scholar]
- Sacheck, J.M.; Ohtsuka, A.; McLary, S.C.; Goldberg, A.L. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab. 2004, 287, E591–E601. [Google Scholar] [CrossRef] [Green Version]
- Yoshida, T.; Semprun-Prieto, L.; Sukhanov, S.; Delafontaine, P. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol. 2010, 298, H1565–H1570. [Google Scholar] [CrossRef] [Green Version]
- Lagirand-Cantaloube, J.; Offner, N.; Csibi, A.; Leibovitch, M.P.; Batonnet-Pichon, S.; Tintignac, L.A.; Segura, C.T.; Leibovitch, S.A. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J. 2008, 27, 1266–1276. [Google Scholar] [CrossRef] [Green Version]
- Lokireddy, S.; Wijesoma, I.W.; Sze, S.K.; McFarlane, C.; Kambadur, R.; Sharma, M. Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am. J. Physiol. Cell Physiol. 2012, 303, C512–C529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Clarke, B.A.; Drujan, D.; Willis, M.S.; Murphy, L.O.; Corpina, R.A.; Burova, E.; Rakhilin, S.V.; Stitt, T.N.; Patterson, C.; Latres, E.; et al. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007, 6, 376–385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cohen, S.; Brault, J.J.; Gygi, S.P.; Glass, D.J.; Valenzuela, D.M.; Gartner, C.; Latres, E.; Goldberg, A.L. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 2009, 185, 1083–1095. [Google Scholar] [CrossRef] [Green Version]
- McElhinny, A.S.; Kakinuma, K.; Sorimachi, H.; Labeit, S.; Gregorio, C.C. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J. Cell Biol. 2002, 157, 125–136. [Google Scholar] [CrossRef] [PubMed]
- Koyama, S.; Hata, S.; Witt, C.C.; Ono, Y.; Lerche, S.; Ojima, K.; Chiba, T.; Doi, N.; Kitamura, F.; Tanaka, K.; et al. Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. J. Mol. Biol. 2008, 376, 1224–1236. [Google Scholar] [CrossRef]
- Hirner, S.; Krohne, C.; Schuster, A.; Hoffmann, S.; Witt, S.; Erber, R.; Sticht, C.; Gasch, A.; Labeit, S.; Labeit, D. MuRF1-dependent regulation of systemic carbohydrate metabolism as revealed from transgenic mouse studies. J. Mol. Biol. 2008, 379, 666–677. [Google Scholar] [CrossRef]
- Milan, G.; Romanello, V.; Pescatore, F.; Armani, A.; Paik, J.H.; Frasson, L.; Seydel, A.; Zhao, J.; Abraham, R.; Goldberg, A.L.; et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat. Commun. 2015, 6, 6670. [Google Scholar] [CrossRef] [Green Version]
- Koncarevic, A.; Jackman, R.W.; Kandarian, S.C. The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension. FASEB J. 2007, 21, 427–437. [Google Scholar] [CrossRef] [Green Version]
- Batt, J.; Bain, J.; Goncalves, J.; Michalski, B.; Plant, P.; Fahnestock, M.; Woodgett, J. Differential gene expression profiling of short and long term denervated muscle. FASEB J. 2006, 20, 115–117. [Google Scholar] [CrossRef]
- Plant, P.J.; Brooks, D.; Faughnan, M.; Bayley, T.; Bain, J.; Singer, L.; Correa, J.; Pearce, D.; Binnie, M.; Batt, J. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2010, 42, 461–471. [Google Scholar] [CrossRef]
- Cao, X.R.; Lill, N.L.; Boase, N.; Shi, P.P.; Croucher, D.R.; Shan, H.; Qu, J.; Sweezer, E.M.; Place, T.; Kirby, P.A.; et al. Nedd4 controls animal growth by regulating IGF-1 signaling. Sci. Signal. 2008, 1, ra5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagpal, P.; Plant, P.J.; Correa, J.; Bain, A.; Takeda, M.; Kawabe, H.; Rotin, D.; Bain, J.R.; Batt, J.A. The ubiquitin ligase Nedd4-1 participates in denervation-induced skeletal muscle atrophy in mice. PLoS ONE 2012, 7, e46427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cohen, S.; Zhai, B.; Gygi, S.P.; Goldberg, A.L. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 2012, 198, 575–589. [Google Scholar] [CrossRef] [PubMed]
- Cohen, S.; Lee, D.; Zhai, B.; Gygi, S.P.; Goldberg, A.L. Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 2014, 204, 747–758. [Google Scholar] [CrossRef] [Green Version]
- Paul, P.K.; Gupta, S.K.; Bhatnagar, S.; Panguluri, S.K.; Darnay, B.G.; Choi, Y.; Kumar, A. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 2010, 191, 1395–1411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paul, P.K.; Bhatnagar, S.; Mishra, V.; Srivastava, S.; Darnay, B.G.; Choi, Y.; Kumar, A. The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol. Cell Biol. 2012, 32, 1248–1259. [Google Scholar] [CrossRef] [Green Version]
- Yang, W.L.; Wang, J.; Chan, C.H.; Lee, S.W.; Campos, A.D.; Lamothe, B.; Hur, L.; Grabiner, B.C.; Lin, X.; Darnay, B.G.; et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009, 325, 1134–1138. [Google Scholar] [CrossRef] [Green Version]
- Malicdan, M.C.; Noguchi, S.; Nonaka, I.; Saftig, P.; Nishino, I. Lysosomal myopathies: An excessive build-up in autophagosomes is too much to handle. Neuromuscul. Disord. 2008, 18, 521–529. [Google Scholar] [CrossRef]
- Masiero, E.; Agatea, L.; Mammucari, C.; Blaauw, B.; Loro, E.; Komatsu, M.; Metzger, D.; Reggiani, C.; Schiaffino, S.; Sandri, M. Autophagy is required to maintain muscle mass. Cell Metab. 2009, 10, 507–515. [Google Scholar] [CrossRef]
- Zhao, J.; Brault, J.J.; Schild, A.; Cao, P.; Sandri, M.; Schiaffino, S.; Lecker, S.H.; Goldberg, A.L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007, 6, 472–483. [Google Scholar] [CrossRef] [Green Version]
- Mammucari, C.; Milan, G.; Romanello, V.; Masiero, E.; Rudolf, R.; Del Piccolo, P.; Burden, S.J.; Di Lisi, R.; Sandri, C.; Zhao, J.; et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007, 6, 458–471. [Google Scholar] [CrossRef] [PubMed]
- Castets, P.; Lin, S.; Rion, N.; Fulvio, S.D.; Romanino, K.; Guridi, M.; Frank, S.; Tintignac, L.A.; Sinnreich, M.; Rüegg, M.A. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 2013, 17, 731–744. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fullgrabe, J.; Ghislat, G.; Cho, D.H.; Rubinsztein, D.C. transcriptional regulation of mammalian autophagy at a glance. J. Cell Sci. 2016, 129, 3059–3066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakashima, K.; Ishida, A. Regulation of autophagy in chick myotubes: Effects of insulin, insulin-like growth factor-I., and amino acids. J. Poult. Sci. 2018, 55, 257–262. [Google Scholar] [CrossRef]
- Ascenzi, F.; Barberi, L.; Dobrowolny, G.; Villa Nova Bacurau, A.; Nicoletti, C.; Rizzuto, E.; Rosenthal, N.; Scicchitano, B.M.; Musaro, A. Effects of IGF-1 isoforms on muscle growth and sarcopenia. Aging Cell 2019, 18, e12954. [Google Scholar] [CrossRef]
- Mizushima, N.; Yoshimori, T.; Levine, B. Methods in mammalian autophagy research. Cell 2010, 140, 313–326. [Google Scholar] [CrossRef] [Green Version]
- Wang, S.; Gu, K. Insulin-like growth factor 1 inhibits autophagy of human colorectal carcinoma drug-resistant cells via the protein kinase B/mammalian target of rapamycin signaling pathway. Mol. Med. Rep. 2018, 17, 2952–2956. [Google Scholar] [CrossRef] [Green Version]
- Yang, M.; Wen, T.; Chen, H.; Deng, J.; Yang, C.; Zhang, Z. Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: Role of autophagy. Stem Cell Res. Ther. 2018, 9, 284. [Google Scholar] [CrossRef]
- Bitto, A.; Lerner, C.; Torres, C.; Roell, M.; Malaguti, M.; Perez, V.; Lorenzini, A.; Hrelia, S.; Ikeno, Y.; Matzko, M.E.; et al. Long-term IGF-I exposure decreases autophagy and cell viability. PLoS ONE 2010, 5, e12592. [Google Scholar] [CrossRef] [Green Version]
- Sandri, M. Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 2013, 45, 2121–2129. [Google Scholar] [CrossRef] [Green Version]
- Aversa, Z.; Pin, F.; Lucia, S.; Penna, F.; Verzaro, R.; Fazi, M.; Colasante, G.; Tirone, A.; Rossi Fanelli, F.; Ramaccini, C.; et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. 2016, 6, 30340. [Google Scholar] [CrossRef] [PubMed]
- Silva, K.A.S.; Ghiarone, T.; Schreiber, K.; Grant, D.; White, T.; Frisard, M.I.; Sukhanov, S.; Chandrasekar, B.; Delafontaine, P.; Yoshida, T. Angiotensin II suppresses autophagy and disrupts ultrastructural morphology and function of mitochondria in mouse skeletal muscle. J. Appl. Physiol. 2019, 126, 1550–1562. [Google Scholar] [CrossRef] [PubMed]
- Costelli, P.; Muscaritoli, M.; Bossola, M.; Penna, F.; Reffo, P.; Bonetto, A.; Busquets, S.; Bonelli, G.; Lopez-Soriano, F.J.; Doglietto, G.B.; et al. IGF-1 is downregulated in experimental cancer cachexia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291, R674–R683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brink, M.; Wellen, J.; Delafontaine, P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Investig. 1996, 97, 2509–2516. [Google Scholar] [CrossRef] [Green Version]
- Schmidt, K.; von Haehling, S.; Doehner, W.; Palus, S.; Anker, S.D.; Springer, J. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. J. Cachexia Sarcopenia Muscle 2011, 2, 105–109. [Google Scholar] [CrossRef]
- Song, Y.H.; Li, Y.; Du, J.; Mitch, W.E.; Rosenthal, N.; Delafontaine, P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Investig. 2005, 115, 451–458. [Google Scholar] [CrossRef] [Green Version]
- Penna, F.; Ballaro, R.; Martinez-Cristobal, P.; Sala, D.; Sebastian, D.; Busquets, S.; Muscaritoli, M.; Argiles, J.M.; Costelli, P.; Zorzano, A. Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. 2019, 431, 2674–2686. [Google Scholar] [CrossRef]
- Thomson, D.M. The role of AMPK in the regulation of skeletal muscle size, hypertrophy, and regeneration. Int. J. Mol. Sci. 2018, 19, 3125. [Google Scholar] [CrossRef] [Green Version]
- Lantier, L.; Mounier, R.; Leclerc, J.; Pende, M.; Foretz, M.; Viollet, B. Coordinated maintenance of muscle cell size control by AMP-activated protein kinase. FASEB J. 2010, 24, 3555–3561. [Google Scholar] [CrossRef] [Green Version]
- Mu, J.; Barton, E.R.; Birnbaum, M.J. Selective suppression of AMP-activated protein kinase in skeletal muscle: Update on ‘lazy mice’. Biochem. Soc. Trans. 2003, 31, 236–241. [Google Scholar] [CrossRef]
- O’Neill, H.M.; Maarbjerg, S.J.; Crane, J.D.; Jeppesen, J.; Jorgensen, S.B.; Schertzer, J.D.; Shyroka, O.; Kiens, B.; van Denderen, B.J.; Tarnopolsky, M.A.; et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc. Natl. Acad. Sci. USA 2011, 108, 16092–16097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gordon, S.E.; Lake, J.A.; Westerkamp, C.M.; Thomson, D.M. Does AMP-activated protein kinase negatively mediate aged fast-twitch skeletal muscle mass? Exerc. Sport Sci. Rev. 2008, 36, 179–186. [Google Scholar] [CrossRef] [Green Version]
- Mounier, R.; Lantier, L.; Leclerc, J.; Sotiropoulos, A.; Pende, M.; Daegelen, D.; Sakamoto, K.; Foretz, M.; Viollet, B. Important role for AMPKalpha1 in limiting skeletal muscle cell hypertrophy. FASEB J. 2009, 23, 2264–2273. [Google Scholar] [CrossRef] [PubMed]
- Hilder, T.L.; Baer, L.A.; Fuller, P.M.; Fuller, C.A.; Grindeland, R.E.; Wade, C.E.; Graves, L.M. Insulin-independent pathways mediating glucose uptake in hindlimb-suspended skeletal muscle. J. Appl. Physiol. 2005, 99, 2181–2188. [Google Scholar] [CrossRef]
- Han, B.; Zhu, M.J.; Ma, C.; Du, M. Rat hindlimb unloading down-regulates insulin like growth factor-1 signaling and AMP-activated protein kinase, and leads to severe atrophy of the soleus muscle. Appl. Physiol. Nutr. Metab. 2007, 32, 1115–1123. [Google Scholar] [CrossRef]
- Liu, J.; Peng, Y.; Cui, Z.; Wu, Z.; Qian, A.; Shang, P.; Qu, L.; Li, Y.; Liu, J.; Long, J. Depressed mitochondrial biogenesis and dynamic remodeling in mouse tibialis anterior and gastrocnemius induced by 4-week hindlimb unloading. IUBMB Life 2012, 64, 901–910. [Google Scholar] [CrossRef] [Green Version]
- Cannavino, J.; Brocca, L.; Sandri, M.; Grassi, B.; Bottinelli, R.; Pellegrino, M.A. The role of alterations in mitochondrial dynamics and PGC-1alpha over-expression in fast muscle atrophy following hindlimb unloading. J. Physiol. 2015, 593, 1981–1995. [Google Scholar] [CrossRef] [Green Version]
- Egawa, T.; Goto, A.; Ohno, Y.; Yokoyama, S.; Ikuta, A.; Suzuki, M.; Sugiura, T.; Ohira, Y.; Yoshioka, T.; Hayashi, T.; et al. Involvement of AMPK in regulating slow-twitch muscle atrophy during hindlimb unloading in mice. Am. J. Physiol. Endocrinol. Metab. 2015, 309, E651–E662. [Google Scholar] [CrossRef]
- Guo, Y.; Meng, J.; Tang, Y.; Wang, T.; Wei, B.; Feng, R.; Gong, B.; Wang, H.; Ji, G.; Lu, Z. AMP-activated kinase alpha2 deficiency protects mice from denervation-induced skeletal muscle atrophy. Arch. Biochem. Biophys. 2016, 600, 56–60. [Google Scholar] [CrossRef]
- Tabony, A.M.; Yoshida, T.; Galvez, S.; Higashi, Y.; Sukhanov, S.; Chandrasekar, B.; Mitch, W.E.; Delafontaine, P. Angiotensin II upregulates protein phosphatase 2Calpha and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension 2011, 58, 643–649. [Google Scholar] [CrossRef] [Green Version]
- Tabony, A.M.; Yoshida, T.; Sukhanov, S.; Delafontaine, P. Protein phosphatase 2C-alpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function. Skelet. Muscle 2014, 4, 20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanchez, A.M.; Candau, R.; Bernardi, H. Recent data on cellular component turnover: Focus on adaptations to physical exercise. Cells 2019, 8, 542. [Google Scholar] [CrossRef] [Green Version]
- Bikle, D.D.; Tahimic, C.; Chang, W.; Wang, Y.; Philippou, A.; Barton, E.R. Role of IGF-I signaling in muscle bone interactions. Bone 2015, 80, 79–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Temmerman, L.; Slonimsky, E.; Rosenthal, N. Class 2 IGF-1 isoforms are dispensable for viability, growth and maintenance of IGF-1 serum levels. Growth Horm. IGF Res. 2010, 20, 255–263. [Google Scholar] [CrossRef] [PubMed]
- Annibalini, G.; Contarelli, S.; De Santi, M.; Saltarelli, R.; Di Patria, L.; Guescini, M.; Villarini, A.; Brandi, G.; Stocchi, V.; Barbieri, E. The intrinsically disordered E-domains regulate the IGF-1 prohormones stability, subcellular localisation and secretion. Sci. Rep. 2018, 8, 8919. [Google Scholar] [CrossRef] [PubMed]
- Durzynska, J.; Philippou, A.; Brisson, B.K.; Nguyen-McCarty, M.; Barton, E.R. The pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation. Endocrinology 2013, 154, 1215–1224. [Google Scholar] [CrossRef] [Green Version]
- Guler, H.P.; Zapf, J.; Schmid, C.; Froesch, E.R. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol. 1989, 121, 753–758. [Google Scholar] [CrossRef]
- Rajaram, S.; Baylink, D.J.; Mohan, S. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions. Endocr. Rev. 1997, 18, 801–831. [Google Scholar] [CrossRef] [Green Version]
- Lewitt, M.S.; Saunders, H.; Phuyal, J.L.; Baxter, R.C. Complex formation by human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth hormone-deficient rats. Endocrinology 1994, 134, 2404–2409. [Google Scholar] [CrossRef]
- Yakar, S.; Rosen, C.J.; Bouxsein, M.L.; Sun, H.; Mejia, W.; Kawashima, Y.; Wu, Y.; Emerton, K.; Williams, V.; Jepsen, K.; et al. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J. 2009, 23, 709–719. [Google Scholar] [CrossRef]
- Jones, J.I.; Clemmons, D.R. Insulin-like growth factors and their binding proteins: Biological actions. Endocr. Rev. 1995, 16, 3–34. [Google Scholar] [CrossRef] [PubMed]
- Daughaday, W.H.; Rotwein, P. Insulin-like growth factors I. and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 1989, 10, 68–91. [Google Scholar] [CrossRef] [PubMed]
- Jogie-Brahim, S.; Feldman, D.; Oh, Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr. Rev. 2009, 30, 417–437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oliver, W.T.; Rosenberger, J.; Lopez, R.; Gomez, A.; Cummings, K.K.; Fiorotto, M.L. The local expression and abundance of insulin-like growth factor (IGF) binding proteins in skeletal muscle are regulated by age and gender but not local IGF-I in vivo. Endocrinology 2005, 146, 5455–5462. [Google Scholar] [CrossRef] [Green Version]
- Huang, X.Y.; Huang, Z.L.; Yang, J.H.; Xu, Y.H.; Sun, J.S.; Zheng, Q.; Wei, C.; Song, W.; Yuan, Z. Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting. J. Exp. Clin. Cancer Res. 2016, 35, 46. [Google Scholar] [CrossRef] [Green Version]
- Salih, D.A.; Tripathi, G.; Holding, C.; Szestak, T.A.; Gonzalez, M.I.; Carter, E.J.; Cobb, L.J.; Eisemann, J.E.; Pell, J.M. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc. Natl. Acad. Sci. USA 2004, 101, 4314–4319. [Google Scholar] [CrossRef] [Green Version]
- Swiderski, K.; Martins, K.J.; Chee, A.; Trieu, J.; Naim, T.; Gehrig, S.M.; Baum, D.M.; Brenmoehl, J.; Chau, L.; Koopman, R.; et al. Skeletal muscle-specific overexpression of IGFBP-2 promotes a slower muscle phenotype in healthy but not dystrophic mdx mice and does not affect the dystrophic pathology. Growth Horm. IGF Res. 2016, 30–31, 1–10. [Google Scholar] [CrossRef]
- Ning, Y.; Schuller, A.G.; Bradshaw, S.; Rotwein, P.; Ludwig, T.; Frystyk, J.; Pintar, J.E. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol. Endocrinol. 2006, 20, 2173–2186. [Google Scholar] [CrossRef]
- Yakar, S.; Liu, J.L.; Stannard, B.; Butler, A.; Accili, D.; Sauer, B.; LeRoith, D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 1999, 96, 7324–7329. [Google Scholar] [CrossRef] [Green Version]
- Sjogren, K.; Liu, J.L.; Blad, K.; Skrtic, S.; Vidal, O.; Wallenius, V.; LeRoith, D.; Tornell, J.; Isaksson, O.G.; Jansson, J.O.; et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. USA 1999, 96, 7088–7092. [Google Scholar] [CrossRef] [Green Version]
- Stratikopoulos, E.; Szabolcs, M.; Dragatsis, I.; Klinakis, A.; Efstratiadis, A. The hormonal action of IGF1 in postnatal mouse growth. Proc. Natl. Acad. Sci. USA 2008, 105, 19378–19383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barton-Davis, E.R.; Shoturma, D.I.; Sweeney, H.L. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol. Scand. 1999, 167, 301–305. [Google Scholar] [CrossRef] [PubMed]
- Musaro, A.; McCullagh, K.; Paul, A.; Houghton, L.; Dobrowolny, G.; Molinaro, M.; Barton, E.R.; Sweeney, H.L.; Rosenthal, N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 2001, 27, 195–200. [Google Scholar] [CrossRef] [PubMed]
- Coleman, M.E.; DeMayo, F.; Yin, K.C.; Lee, H.M.; Geske, R.; Montgomery, C.; Schwartz, R.J. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 1995, 270, 12109–12116. [Google Scholar] [CrossRef] [Green Version]
- Schakman, O.; Gilson, H.; de Coninck, V.; Lause, P.; Verniers, J.; Havaux, X.; Ketelslegers, J.M.; Thissen, J.P. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 2005, 146, 1789–1797. [Google Scholar] [CrossRef] [Green Version]
- Criswell, D.S.; Booth, F.W.; DeMayo, F.; Schwartz, R.J.; Gordon, S.E.; Fiorotto, M.L. Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy. Am. J. Physiol. 1998, 275, E373–E379. [Google Scholar] [CrossRef]
- Mavalli, M.D.; DiGirolamo, D.J.; Fan, Y.; Riddle, R.C.; Campbell, K.S.; van Groen, T.; Frank, S.J.; Sperling, M.A.; Esser, K.A.; Bamman, M.M.; et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J. Clin. Investig. 2010, 120, 4007–4020. [Google Scholar] [CrossRef] [Green Version]
- O’Neill, B.T.; Lauritzen, H.P.; Hirshman, M.F.; Smyth, G.; Goodyear, L.J.; Kahn, C.R. Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep. 2015, 11, 1220–1235. [Google Scholar] [CrossRef] [Green Version]
- Engert, J.C.; Berglund, E.B.; Rosenthal, N. Proliferation precedes differentiation in IGF-I-stimulated myogenesis. J. Cell Biol. 1996, 135, 431–440. [Google Scholar] [CrossRef]
- Musaro, A.; Rosenthal, N. Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Mol. Cell Biol. 1999, 19, 3115–3124. [Google Scholar] [CrossRef] [Green Version]
- Coolican, S.A.; Samuel, D.S.; Ewton, D.Z.; McWade, F.J.; Florini, J.R. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J. Biol. Chem. 1997, 272, 6653–6662. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chakravarthy, M.V.; Abraha, T.W.; Schwartz, R.J.; Fiorotto, M.L.; Booth, F.W. Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3′-kinase/Akt signaling pathway. J. Biol. Chem. 2000, 275, 35942–35952. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heslop, L.; Morgan, J.E.; Partridge, T.A. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J. Cell Sci. 2000, 113 Pt 12, 2299–2308. [Google Scholar]
- Egner, I.M.; Bruusgaard, J.C.; Gundersen, K. Satellite cell depletion prevents fiber hypertrophy in skeletal muscle. Development 2016, 143, 2898–2906. [Google Scholar] [CrossRef] [Green Version]
- McCarthy, J.J.; Mula, J.; Miyazaki, M.; Erfani, R.; Garrison, K.; Farooqui, A.B.; Srikuea, R.; Lawson, B.A.; Grimes, B.; Keller, C.; et al. Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. Development 2011, 138, 3657–3666. [Google Scholar] [CrossRef] [Green Version]
- Ates, K.; Yang, S.Y.; Orrell, R.W.; Sinanan, A.C.; Simons, P.; Solomon, A.; Beech, S.; Goldspink, G.; Lewis, M.P. The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle. FEBS Lett. 2007, 581, 2727–2732. [Google Scholar] [CrossRef] [Green Version]
- Goldspink, G. Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting. Int. J. Biochem. Cell Biol. 2006, 38, 481–489. [Google Scholar] [CrossRef]
- Hameed, M.; Orrell, R.W.; Cobbold, M.; Goldspink, G.; Harridge, S.D. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol 2003, 547, 247–254. [Google Scholar] [CrossRef]
- Owino, V.; Yang, S.Y.; Goldspink, G. Age-related loss of skeletal muscle function and the inability to express the autocrine form of insulin-like growth factor-1 (MGF) in response to mechanical overload. Febs Lett 2001, 505, 259–263. [Google Scholar] [CrossRef]
- Yang, S.Y.; Goldspink, G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002, 522, 156–160. [Google Scholar] [CrossRef] [Green Version]
- Kandalla, P.K.; Goldspink, G.; Butler-Browne, G.; Mouly, V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech. Ageing Dev. 2011, 132, 154–162. [Google Scholar] [CrossRef]
- Fornaro, M.; Hinken, A.C.; Needle, S.; Hu, E.; Trendelenburg, A.U.; Mayer, A.; Rosenstiel, A.; Chang, C.; Meier, V.; Billin, A.N.; et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am. J. Physiol. Endocrinol. Metab. 2014, 306, E150–E156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shavlakadze, T.; Chai, J.; Maley, K.; Cozens, G.; Grounds, G.; Winn, N.; Rosenthal, N.; Grounds, M.D. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J. Cell Sci. 2010, 123, 960–971. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elia, D.; Madhala, D.; Ardon, E.; Reshef, R.; Halevy, O. Sonic hedgehog promotes proliferation and differentiation of adult muscle cells: Involvement of MAPK/ERK and PI3K/Akt pathways. Biochim. Biophys. Acta 2007, 1773, 1438–1446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koleva, M.; Kappler, R.; Vogler, M.; Herwig, A.; Fulda, S.; Hahn, H. Pleiotropic effects of sonic hedgehog on muscle satellite cells. Cell Mol. Life Sci. 2005, 62, 1863–1870. [Google Scholar] [CrossRef]
- Madhala-Levy, D.; Williams, V.C.; Hughes, S.M.; Reshef, R.; Halevy, O. Cooperation between Shh and IGF-I in promoting myogenic proliferation and differentiation via the MAPK/ERK and PI3K/Akt pathways requires Smo activity. J. Cell Physiol. 2012, 227, 1455–1464. [Google Scholar] [CrossRef] [Green Version]
- Zecchini, S.; Giovarelli, M.; Perrotta, C.; Morisi, F.; Touvier, T.; Di Renzo, I.; Moscheni, C.; Bassi, M.T.; Cervia, D.; Sandri, M.; et al. Autophagy controls neonatal myogenesis by regulating the GH-IGF1 system through a NFE2L2- and DDIT3-mediated mechanism. Autophagy 2019, 15, 58–77. [Google Scholar] [CrossRef] [Green Version]
- Li, J.; Chan, M.C.; Yu, Y.; Bei, Y.; Chen, P.; Zhou, Q.; Cheng, L.; Chen, L.; Ziegler, O.; Rowe, G.C.; et al. miR-29b contributes to multiple types of muscle atrophy. Nat. Commun. 2017, 8, 15201. [Google Scholar] [CrossRef] [Green Version]
- Goodman, C.A.; McNally, R.M.; Hoffmann, F.M.; Hornberger, T.A. Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo. Mol. Endocrinol. 2013, 27, 1946–1957. [Google Scholar] [CrossRef]
- Wang, X.H.; Hu, Z.; Klein, J.D.; Zhang, L.; Fang, F.; Mitch, W.E. Decreased miR-29 suppresses myogenesis in CKD. J. Am. Soc. Nephrol. 2011, 22, 2068–2076. [Google Scholar] [CrossRef] [Green Version]
- Wang, H.; Wang, B.; Zhang, A.; Hassounah, F.; Seow, Y.; Wood, M.; Ma, F.; Klein, J.D.; Price, S.R.; Wang, X.H. Exosome-mediated miR-29 transfer reduces muscle atrophy and kidney fibrosis in mice. Mol. Ther. 2019, 27, 571–583. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blattler, S.M.; Cunningham, J.T.; Verdeguer, F.; Chim, H.; Haas, W.; Liu, H.; Romanino, K.; Ruegg, M.A.; Gygi, S.P.; Shi, Y.; et al. Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab. 2012, 15, 505–517. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ge, Y.; Chen, J. MicroRNAs in skeletal myogenesis. Cell Cycle 2011, 10, 441–448. [Google Scholar] [CrossRef] [Green Version]
- McCarthy, J.J.; Esser, K.A. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J. Appl. Physiol. 2007, 102, 306–313. [Google Scholar] [CrossRef]
- Elia, L.; Contu, R.; Quintavalle, M.; Varrone, F.; Chimenti, C.; Russo, M.A.; Cimino, V.; De Marinis, L.; Frustaci, A.; Catalucci, D.; et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009, 120, 2377–2385. [Google Scholar] [CrossRef]
- Huang, M.B.; Xu, H.; Xie, S.J.; Zhou, H.; Qu, L.H. Insulin-like growth factor-1 receptor is regulated by microRNA-133 during skeletal myogenesis. PLoS ONE 2011, 6, e29173. [Google Scholar] [CrossRef] [Green Version]
- Kukreti, H.; Amuthavalli, K.; Harikumar, A.; Sathiyamoorthy, S.; Feng, P.Z.; Anantharaj, R.; Tan, S.L.; Lokireddy, S.; Bonala, S.; Sriram, S.; et al. Muscle-specific microRNA1 (miR1) targets heat shock protein 70 (HSP70) during dexamethasone-mediated atrophy. J. Biol. Chem. 2013, 288, 6663–6678. [Google Scholar] [CrossRef] [Green Version]
- Motohashi, N.; Alexander, M.S.; Shimizu-Motohashi, Y.; Myers, J.A.; Kawahara, G.; Kunkel, L.M. Regulation of IRS1/Akt insulin signaling by microRNA-128a during myogenesis. J. Cell Sci. 2013, 126, 2678–2691. [Google Scholar] [CrossRef] [Green Version]
- Porter, N.C.; Resneck, W.G.; O’Neill, A.; Van Rossum, D.B.; Stone, M.R.; Bloch, R.J. Association of small ankyrin 1 with the sarcoplasmic reticulum. Mol. Membr. Biol. 2005, 22, 421–432. [Google Scholar] [CrossRef]
- Zhou, L.; Wang, L.; Lu, L.; Jiang, P.; Sun, H.; Wang, H. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PLoS ONE 2012, 7, e33766. [Google Scholar] [CrossRef] [Green Version]
- Small, E.M.; O’Rourke, J.R.; Moresi, V.; Sutherland, L.B.; McAnally, J.; Gerard, R.D.; Richardson, J.A.; Olson, E.N. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc. Natl. Acad. Sci. USA 2010, 107, 4218–4223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hitachi, K.; Nakatani, M.; Tsuchida, K. Myostatin signaling regulates Akt activity via the regulation of miR-486 expression. Int. J. Biochem. Cell Biol. 2014, 47, 93–103. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.; Li, R.; Workeneh, B.; Dong, Y.; Wang, X.; Hu, Z. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 2012, 82, 401–411. [Google Scholar] [CrossRef] [Green Version]
- Lopez-Urrutia, E.; Bustamante Montes, L.P.; Ladron de Guevara Cervantes, D.; Perez-Plasencia, C.; Campos-Parra, A.D. Crosstalk between long non-coding RNAs, Micro-RNAs and mRNAs: Deciphering molecular mechanisms of master regulators in cancer. Front. Oncol. 2019, 9, 669. [Google Scholar] [CrossRef]
- Li, Z.; Cai, B.; Abdalla, B.A.; Zhu, X.; Zheng, M.; Han, P.; Nie, Q.; Zhang, X. LncIRS1 controls muscle atrophy via sponging miR-15 family to activate IGF1-PI3K/AKT pathway. J. Cachexia Sarcopenia Muscle 2019, 10, 391–410. [Google Scholar] [CrossRef] [Green Version]
- Park, S.; Brisson, B.K.; Liu, M.; Spinazzola, J.M.; Barton, E.R. Mature IGF-I excels in promoting functional muscle recovery from disuse atrophy compared with pro-IGF-IA. J. Appl. Physiol. 2014, 116, 797–806. [Google Scholar] [CrossRef]
- Dobrowolny, G.; Giacinti, C.; Pelosi, L.; Nicoletti, C.; Winn, N.; Barberi, L.; Molinaro, M.; Rosenthal, N.; Musaro, A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005, 168, 193–199. [Google Scholar] [CrossRef] [Green Version]
- Barton, E.R.; Morris, L.; Musaro, A.; Rosenthal, N.; Sweeney, H.L. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 2002, 157, 137–148. [Google Scholar] [CrossRef] [Green Version]
- Kumar, A.; Yamauchi, J.; Girgenrath, T.; Girgenrath, M. Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum. Mol. Genet. 2011, 20, 2333–2343. [Google Scholar] [CrossRef] [Green Version]
- Shavlakadze, T.; White, J.; Hoh, J.F.; Rosenthal, N.; Grounds, M.D. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol. Ther. 2004, 10, 829–843. [Google Scholar] [CrossRef]
- Baker, J.F.; Von Feldt, J.M.; Mostoufi-Moab, S.; Kim, W.; Taratuta, E.; Leonard, M.B. Insulin-like Growth Factor 1 and Adiponectin and Associations with Muscle Deficits, Disease Characteristics, and Treatments in Rheumatoid Arthritis. J. Rheumatol. 2015, 42, 2038–2045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lopez-Menduina, M.; Martin, A.I.; Castillero, E.; Villanua, M.A.; Lopez-Calderon, A. Systemic IGF-I administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius mass and decreases atrogin-1 and IGFBP-3. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299, R541–R551. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- AsghariHanjani, N.; Vafa, M. The role of IGF-1 in obesity, cardiovascular disease, and cancer. Med. J. Islam. Repub. Iran 2019, 33, 56. [Google Scholar] [CrossRef] [PubMed]
- White, J.P.; Baynes, J.W.; Welle, S.L.; Kostek, M.C.; Matesic, L.E.; Sato, S.; Carson, J.A. The Regulation of Skeletal Muscle Protein Turnover during the Progression of Cancer Cachexia in the ApcMin/ + Mouse. PLoS ONE 2011, 6, e24650. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bonetto, A.; Penna, F.; Aversa, Z.; Mercantini, P.; Baccino, F.M.; Costelli, P.; Ziparo, V.; Lucia, S.; Rossi Fanelli, F.; Muscaritoli, M. Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. Muscle Nerve 2013, 48, 387–392. [Google Scholar] [CrossRef]
- Penna, F.; Bonetto, A.; Muscaritoli, M.; Costamagna, D.; Minero, V.G.; Bonelli, G.; Fanelli, F.R.; Baccino, F.M.; Costelli, P. Muscle atrophy in experimental cancer cachexia: Is the IGF-1 signaling pathway involved? Int. J. Cancer 2010, 127, 1706–1717. [Google Scholar] [CrossRef]
- Ungvari, Z.; Csiszar, A. The emerging role of IGF-1 deficiency in cardiovascular aging: Recent advances. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 599–610. [Google Scholar] [CrossRef] [Green Version]
- Laughlin, G.A.; Barrett-Connor, E.; Criqui, M.H.; Kritz-Silverstein, D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: The rancho bernardo study. J. Clin. Endocrinol. Metab. 2004, 89, 114–120. [Google Scholar] [CrossRef] [Green Version]
- Conti, E.; Carrozza, C.; Capoluongo, E.; Volpe, M.; Crea, F.; Zuppi, C.; Andreotti, F. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004, 110, 2260–2265. [Google Scholar] [CrossRef]
- Bailey-Downs, L.C.; Mitschelen, M.; Sosnowska, D.; Toth, P.; Pinto, J.T.; Ballabh, P.; Valcarcel-Ares, M.N.; Farley, J.; Koller, A.; Henthorn, J.C.; et al. Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: A novel model of vascular aging. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 313–329. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Ceylan-Isik, A.F.; Li, J.; Ren, J. Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction. Rejuvenation Res. 2008, 11, 725–733. [Google Scholar] [CrossRef] [Green Version]
- Schulze, P.C.; Fang, J.; Kassik, K.A.; Gannon, J.; Cupesi, M.; MacGillivray, C.; Lee, R.T.; Rosenthal, N. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ. Res. 2005, 97, 418–426. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Araki, S.; Izumiya, Y.; Hanatani, S.; Rokutanda, T.; Usuku, H.; Akasaki, Y.; Takeo, T.; Nakagata, N.; Walsh, K.; Ogawa, H. Akt1-mediated skeletal muscle growth attenuates cardiac dysfunction and remodeling after experimental myocardial infarction. Circ. Heart Fail. 2012, 5, 116–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Price, S.R.; Gooch, J.L.; Donaldson, S.K.; Roberts-Wilson, T.K. Muscle atrophy in chronic kidney disease results from abnormalities in insulin signaling. J. Ren. Nutr. 2010, 20, S24–S28. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.H.; Mitch, W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014, 10, 504–516. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.Y.; Gu, L.J.; Huang, J.; Cai, M.C.; Yu, H.L.; Zhang, W.; Bao, J.F.; Yuan, W.J. CKD autophagy activation and skeletal muscle atrophy-a preliminary study of mitophagy and inflammation. Eur. J. Clin. Nutr. 2019, 73, 950–960. [Google Scholar] [CrossRef]
- Barreiro, E.; Jaitovich, A. Muscle atrophy in chronic obstructive pulmonary disease: Molecular basis and potential therapeutic targets. J. Thorac. Dis. 2018, 10, S1415–S1424. [Google Scholar] [CrossRef]
- Maltais, F.; Decramer, M.; Casaburi, R.; Barreiro, E.; Burelle, Y.; Debigare, R.; Dekhuijzen, P.N.; Franssen, F.; Gayan-Ramirez, G.; Gea, J.; et al. An official american thoracic society/european respiratory society statement: Update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2014, 189, e15–e62. [Google Scholar] [CrossRef] [Green Version]
- Marquis, K.; Debigare, R.; Lacasse, Y.; LeBlanc, P.; Jobin, J.; Carrier, G.; Maltais, F. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002, 166, 809–813. [Google Scholar] [CrossRef]
- Shrikrishna, D.; Patel, M.; Tanner, R.J.; Seymour, J.M.; Connolly, B.A.; Puthucheary, Z.A.; Walsh, S.L.; Bloch, S.A.; Sidhu, P.S.; Hart, N.; et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur. Respir. J. 2012, 40, 1115–1122. [Google Scholar] [CrossRef] [Green Version]
- Swallow, E.B.; Reyes, D.; Hopkinson, N.S.; Man, W.D.; Porcher, R.; Cetti, E.J.; Moore, A.J.; Moxham, J.; Polkey, M.I. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007, 62, 115–120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Doucet, M.; Russell, A.P.; Leger, B.; Debigare, R.; Joanisse, D.R.; Caron, M.A.; LeBlanc, P.; Maltais, F. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007, 176, 261–269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Theriault, M.E.; Pare, M.E.; Maltais, F.; Debigare, R. Satellite cells senescence in limb muscle of severe patients with COPD. PLoS ONE 2012, 7, e39124. [Google Scholar] [CrossRef] [PubMed]
- Theriault, M.E.; Pare, M.E.; Lemire, B.B.; Maltais, F.; Debigare, R. Regenerative defect in vastus lateralis muscle of patients with chronic obstructive pulmonary disease. Respir. Res. 2014, 15, 35. [Google Scholar] [CrossRef] [Green Version]
- Piehl-Aulin, K.; Jones, I.; Lindvall, B.; Magnuson, A.; Abdel-Halim, S.M. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration 2009, 78, 191–196. [Google Scholar] [CrossRef]
- Debigare, R.; Marquis, K.; Cote, C.H.; Tremblay, R.R.; Michaud, A.; LeBlanc, P.; Maltais, F. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003, 124, 83–89. [Google Scholar] [CrossRef] [Green Version]
- Crul, T.; Spruit, M.A.; Gayan-Ramirez, G.; Quarck, R.; Gosselink, R.; Troosters, T.; Pitta, F.; Decramer, M. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur. J. Clin. Investig. 2007, 37, 897–904. [Google Scholar] [CrossRef]
- Walston, J.D. Sarcopenia in older adults. Curr. Opin. Rheumatol. 2012, 24, 623–627. [Google Scholar] [CrossRef] [Green Version]
- Leger, B.; Derave, W.; De Bock, K.; Hespel, P.; Russell, A.P. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008, 11, 163–175. [Google Scholar] [CrossRef] [Green Version]
- Cuthbertson, D.; Smith, K.; Babraj, J.; Leese, G.; Waddell, T.; Atherton, P.; Wackerhage, H.; Taylor, P.M.; Rennie, M.J. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J. 2005, 19, 422–424. [Google Scholar] [CrossRef]
- Barton-Davis, E.R.; Shoturma, D.I.; Musaro, A.; Rosenthal, N.; Sweeney, H.L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc. Natl. Acad. Sci. USA 1998, 95, 15603–15607. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gong, Z.; Kennedy, O.; Sun, H.; Wu, Y.; Williams, G.A.; Klein, L.; Cardoso, L.; Matheny, R.W., Jr.; Hubbard, G.B.; Ikeno, Y.; et al. Reductions in serum IGF-1 during aging impair health span. Aging Cell 2014, 13, 408–418. [Google Scholar] [CrossRef] [PubMed]
- Sandri, M.; Barberi, L.; Bijlsma, A.Y.; Blaauw, B.; Dyar, K.A.; Milan, G.; Mammucari, C.; Meskers, C.G.; Pallafacchina, G.; Paoli, A.; et al. Signalling pathways regulating muscle mass in ageing skeletal muscle: The role of the IGF1-Akt-mTOR-FoxO pathway. Biogerontology 2013, 14, 303–323. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yoshida, T.; Delafontaine, P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells 2020, 9, 1970. https://doi.org/10.3390/cells9091970
Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020; 9(9):1970. https://doi.org/10.3390/cells9091970
Chicago/Turabian StyleYoshida, Tadashi, and Patrice Delafontaine. 2020. "Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy" Cells 9, no. 9: 1970. https://doi.org/10.3390/cells9091970